Beverly Hills Private Wealth LLC Acquires 37 Shares of Amgen Inc. $AMGN

Beverly Hills Private Wealth LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 1,969 shares of the medical research company’s stock after buying an additional 37 shares during the period. Beverly Hills Private Wealth LLC’s holdings in Amgen were worth $550,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. Balboa Wealth Partners lifted its stake in shares of Amgen by 4.6% in the 2nd quarter. Balboa Wealth Partners now owns 986 shares of the medical research company’s stock worth $275,000 after purchasing an additional 43 shares during the period. Cidel Asset Management Inc. increased its holdings in Amgen by 3.1% in the 2nd quarter. Cidel Asset Management Inc. now owns 3,242 shares of the medical research company’s stock worth $905,000 after acquiring an additional 99 shares in the last quarter. BKM Wealth Management LLC increased its holdings in Amgen by 3.7% in the 2nd quarter. BKM Wealth Management LLC now owns 7,402 shares of the medical research company’s stock worth $2,067,000 after acquiring an additional 267 shares in the last quarter. MB Levis & Associates LLC increased its holdings in Amgen by 2.8% in the 2nd quarter. MB Levis & Associates LLC now owns 3,800 shares of the medical research company’s stock worth $1,061,000 after acquiring an additional 104 shares in the last quarter. Finally, Dumont & Blake Investment Advisors LLC increased its holdings in Amgen by 0.7% in the 2nd quarter. Dumont & Blake Investment Advisors LLC now owns 8,911 shares of the medical research company’s stock worth $2,488,000 after acquiring an additional 62 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares in the company, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.69% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the subject of several analyst reports. Weiss Ratings raised shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Citigroup increased their target price on shares of Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a report on Wednesday, September 24th. Raymond James Financial initiated coverage on shares of Amgen in a report on Wednesday, September 3rd. They issued a “market perform” rating for the company. Morgan Stanley increased their target price on shares of Amgen from $330.00 to $333.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $305.00 price objective on shares of Amgen in a report on Tuesday, June 24th. Six equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Amgen has an average rating of “Hold” and a consensus price target of $300.94.

Amgen Stock Up 1.5%

Shares of AMGN opened at $303.33 on Tuesday. The company has a market cap of $163.30 billion, a PE ratio of 24.80, a P/E/G ratio of 2.64 and a beta of 0.49. The business has a fifty day moving average of $287.51 and a 200 day moving average of $287.05. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $335.88. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. The company had revenue of $9.18 billion during the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.Amgen’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the company earned $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, sell-side analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.1%. The ex-dividend date was Friday, August 22nd. Amgen’s dividend payout ratio (DPR) is 77.84%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.